مصطلحات الفهرس: SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily B member 1/ec [Endogenous Compound], transcription factor EZH2/ec [Endogenous Compound], transcriptional regulator ATRX/ec [Endogenous Compound], transcriptome/ec [Endogenous Compound], unclassified drug, cdkn2a/b protein/ec [Endogenous Compound], h3f3a protein/ec [Endogenous Compound], kit protein/ec [Endogenous Compound], mycn protein/ec [Endogenous Compound], nf1 protein/ec [Endogenous Compound], nras protein/ec [Endogenous Compound], pdfgra protein/ec [Endogenous Compound], pik3ca protein/ec [Endogenous Compound], pik3r1 protein/ec [Endogenous Compound], PIK3R2 protein/ec [Endogenous Compound], rb1 protein/ec [Endogenous Compound], protein tyrosine phosphatase SHP 2/ec [Endogenous Compound], epidermal growth factor receptor/ec [Endogenous Compound], adult, article, cancer chemotherapy, cancer patient, cancer risk, cancer susceptibility, central nervous system tumor, childhood cancer/dt [Drug Therapy], chromosome 1q, chromosome arm, classifier, cohort analysis, controlled study, feasibility study, follow up, gene amplification, gene expression, germline mutation, hematologic malignancy, human, loss of function mutation, major clinical study, methylome, molecular fingerprinting, neuroblastoma, pilot study, point mutation, priority journal, prospective study, RNA sequencing, sarcoma, signal transduction, single nucleotide polymorphism, solid malignant neoplasm, treatment response, tumor associated leukocyte, whole genome sequencing, young adult, antineoplastic agent/cb [Drug Combination], antineoplastic agent/dt [Drug Therapy], ATM protein/ec [Endogenous Compound], BRG1 protein/ec [Endogenous Compound], cyclin dependent kinase 4/ec [Endogenous Compound], cyclin dependent kinase inhibitor/cb [Drug Combination], epidermal growth factor receptor 2/ec [Endogenous Compound], fibroblast growth factor receptor 1/ec [Endogenous Compound], mammalian target of rapamycin/ec [Endogenous Compound], mammalian target of rapamycin complex 1/ec [Endogenous Compound], mammalian target of rapamycin complex 2/ec [Endogenous Compound], mammalian target of rapamycin inhibitor/cb [Drug Combination], mammalian target of rapamycin inhibitor/dt [Drug Therapy], Myc protein/ec [Endogenous Compound], nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor/cb [Drug Combination], nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor/dt [Drug Therapy], phosphatidylinositol 3 kinase/ec [Endogenous Compound], phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase/ec [Endogenous Compound], protein/ec [Endogenous Compound], protein kinase B/ec [Endogenous Compound], protein p53/ec [Endogenous Compound], cyclin dependent kinase inhibitor/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/26859Test
Nature Medicine
Click here for full text options
LibKey Link

مصطلحات الفهرس: SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily B member 1/ec [Endogenous Compound], transcription factor EZH2/ec [Endogenous Compound], transcriptional regulator ATRX/ec [Endogenous Compound], transcriptome/ec [Endogenous Compound], unclassified drug, cdkn2a/b protein/ec [Endogenous Compound], h3f3a protein/ec [Endogenous Compound], kit protein/ec [Endogenous Compound], mycn protein/ec [Endogenous Compound], nf1 protein/ec [Endogenous Compound], nras protein/ec [Endogenous Compound], pdfgra protein/ec [Endogenous Compound], pik3ca protein/ec [Endogenous Compound], pik3r1 protein/ec [Endogenous Compound], PIK3R2 protein/ec [Endogenous Compound], rb1 protein/ec [Endogenous Compound], protein tyrosine phosphatase SHP 2/ec [Endogenous Compound], epidermal growth factor receptor/ec [Endogenous Compound], adult, article, cancer chemotherapy, cancer patient, cancer risk, cancer susceptibility, central nervous system tumor, childhood cancer/dt [Drug Therapy], chromosome 1q, chromosome arm, classifier, cohort analysis, controlled study, feasibility study, follow up, gene amplification, gene expression, germline mutation, hematologic malignancy, human, loss of function mutation, major clinical study, methylome, molecular fingerprinting, neuroblastoma, pilot study, point mutation, priority journal, prospective study, RNA sequencing, sarcoma, signal transduction, single nucleotide polymorphism, solid malignant neoplasm, treatment response, tumor associated leukocyte, whole genome sequencing, young adult, antineoplastic agent/cb [Drug Combination], antineoplastic agent/dt [Drug Therapy], ATM protein/ec [Endogenous Compound], BRG1 protein/ec [Endogenous Compound], cyclin dependent kinase 4/ec [Endogenous Compound], cyclin dependent kinase inhibitor/cb [Drug Combination], epidermal growth factor receptor 2/ec [Endogenous Compound], fibroblast growth factor receptor 1/ec [Endogenous Compound], mammalian target of rapamycin/ec [Endogenous Compound], mammalian target of rapamycin complex 1/ec [Endogenous Compound], mammalian target of rapamycin complex 2/ec [Endogenous Compound], mammalian target of rapamycin inhibitor/cb [Drug Combination], mammalian target of rapamycin inhibitor/dt [Drug Therapy], Myc protein/ec [Endogenous Compound], nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor/cb [Drug Combination], nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor/dt [Drug Therapy], phosphatidylinositol 3 kinase/ec [Endogenous Compound], phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase/ec [Endogenous Compound], protein/ec [Endogenous Compound], protein kinase B/ec [Endogenous Compound], protein p53/ec [Endogenous Compound], cyclin dependent kinase inhibitor/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/26859Test
Nature Medicine
LibKey Link

مصطلحات الفهرس: animal tissue, antithrombotic activity, article, carotid artery thrombosis/dt [Drug Therapy], controlled study, enzyme inhibition, ex vivo study, hemostasis, human, human cell, in vivo study, mouse, nonhuman, priority journal, shear stress, thrombocyte adhesion, thrombocyte function, thrombocyte membrane, thrombocyte structure, thrombosis, acetylsalicylic acid/dt [Drug Therapy], copanlisib/pd [Pharmacology], dactolisib/pd [Pharmacology], n (2,3 dihydro 7,8 dimethoxyimidazo[1,2 c]quinazolin 5 yl)nicotinamide/pd [Pharmacology], phosphatidylinositol 3 kinase/ec [Endogenous Compound], phosphatidylinositol 3 kinase inhibitor/dt [Drug Therapy], phosphatidylinositol 3 kinase inhibitor/iv [Intravenous Drug Administration], phosphatidylinositol 3 kinase inhibitor/pd [Pharmacology], unclassified drug, platelet internal membrane, mips 19416/dt [Drug Therapy], mips 19416/iv [Intravenous Drug Administration], mips 19416/pd [Pharmacology], mips 19417/pd [Pharmacology], mips 21335/dt [Drug Therapy], mips 21335/iv [Intravenous Drug Administration], mips 21335/pd [Pharmacology], PI3KC2alpha protein/ec [Endogenous Compound], thrombocyte activation, animal cell, animal experiment, animal model, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28859Test
Science Translational Medicine
Click here for full text options
LibKey Link

مصطلحات الفهرس: animal tissue, antithrombotic activity, article, carotid artery thrombosis/dt [Drug Therapy], controlled study, enzyme inhibition, ex vivo study, hemostasis, human, human cell, in vivo study, mouse, nonhuman, priority journal, shear stress, thrombocyte adhesion, thrombocyte function, thrombocyte membrane, thrombocyte structure, thrombosis, acetylsalicylic acid/dt [Drug Therapy], copanlisib/pd [Pharmacology], dactolisib/pd [Pharmacology], n (2,3 dihydro 7,8 dimethoxyimidazo[1,2 c]quinazolin 5 yl)nicotinamide/pd [Pharmacology], phosphatidylinositol 3 kinase/ec [Endogenous Compound], phosphatidylinositol 3 kinase inhibitor/dt [Drug Therapy], phosphatidylinositol 3 kinase inhibitor/iv [Intravenous Drug Administration], phosphatidylinositol 3 kinase inhibitor/pd [Pharmacology], unclassified drug, platelet internal membrane, mips 19416/dt [Drug Therapy], mips 19416/iv [Intravenous Drug Administration], mips 19416/pd [Pharmacology], mips 19417/pd [Pharmacology], mips 21335/dt [Drug Therapy], mips 21335/iv [Intravenous Drug Administration], mips 21335/pd [Pharmacology], PI3KC2alpha protein/ec [Endogenous Compound], thrombocyte activation, animal cell, animal experiment, animal model, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28859Test
Science Translational Medicine
LibKey Link

مصطلحات الفهرس: human, immunity, immunoregulation, immunosuppressive treatment, ligand binding, lupus vulgaris/dt [Drug Therapy], mesenchymal stem cell, osteoblast, osteoporosis, phenotype, regulatory T lymphocyte, review, rheumatoid arthritis, systemic lupus erythematosus, TATA box, Tfh cell, antinuclear antibody/ec [Endogenous Compound], autoantibody/ec [Endogenous Compound], belimumab, glucocorticoid/dt [Drug Therapy], immunoglobulin enhancer binding protein/ec [Endogenous Compound], interleukin 1/ec [Endogenous Compound], interleukin 10/ec [Endogenous Compound], interleukin 1beta/ec [Endogenous Compound], leucine zipper protein/ec [Endogenous Compound], mitogen activated protein kinase/ec [Endogenous Compound], phosphatidylinositol 3 kinase/ec [Endogenous Compound], protein SH3/ec [Endogenous Compound], STAT3 protein/ec [Endogenous Compound], transcription factor AP 1/ec [Endogenous Compound], transcription factor FOXP3/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], unclassified drug, glucocorticoid induced leucine zipper/ec [Endogenous Compound], genetic polymorphism, antiinflammatory activity, apoptosis, B lymphocyte activation, B lymphocyte differentiation, cardiovascular disease, cell differentiation, chromatin structure, diabetes mellitus, disease activity, disease control, DNA binding, down regulation, gene control, gene expression, genetic transcription, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35608Test
Frontiers in Immunology
Click here for full text options
LibKey Link

مصطلحات الفهرس: autopsy, brain malformation/di [Diagnosis], cerebellum, cerebrospinal fluid, clinical article, corpus callosum agenesis, Dandy Walker syndrome, diagnostic accuracy, diagnostic value, female, fetus, fetus brain, fetus death, fetus echography, gene mutation, genetic screening, gestational age, human, human tissue, intermethod comparison, neuroimaging, nuclear magnetic resonance imaging, phenotype, pregnancy termination, prenatal diagnosis, priority journal, retrospective study, cell adhesion molecule/ec [Endogenous Compound], phosphatidylinositol 3 kinase/ec [Endogenous Compound], protein/ec [Endogenous Compound], nuclear magnetic resonance scanner, L1 cell adhesion molecule/ec [Endogenous Compound], TUBB1 protein/ec [Endogenous Compound], 1.5T Avanto, 3T GE Excite, unclassified drug, article, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36066Test
Neuroradiology
Click here for full text options
LibKey Link

مصطلحات الفهرس: autopsy, brain malformation/di [Diagnosis], cerebellum, cerebrospinal fluid, clinical article, corpus callosum agenesis, Dandy Walker syndrome, diagnostic accuracy, diagnostic value, female, fetus, fetus brain, fetus death, fetus echography, gene mutation, genetic screening, gestational age, human, human tissue, intermethod comparison, neuroimaging, nuclear magnetic resonance imaging, phenotype, pregnancy termination, prenatal diagnosis, priority journal, retrospective study, cell adhesion molecule/ec [Endogenous Compound], phosphatidylinositol 3 kinase/ec [Endogenous Compound], protein/ec [Endogenous Compound], nuclear magnetic resonance scanner, L1 cell adhesion molecule/ec [Endogenous Compound], TUBB1 protein/ec [Endogenous Compound], 1.5T Avanto, 3T GE Excite, unclassified drug, article, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36066Test
Neuroradiology
LibKey Link

مصطلحات الفهرس: human, immunity, immunoregulation, immunosuppressive treatment, ligand binding, lupus vulgaris/dt [Drug Therapy], mesenchymal stem cell, osteoblast, osteoporosis, phenotype, regulatory T lymphocyte, review, rheumatoid arthritis, systemic lupus erythematosus, TATA box, Tfh cell, antinuclear antibody/ec [Endogenous Compound], autoantibody/ec [Endogenous Compound], belimumab, glucocorticoid/dt [Drug Therapy], immunoglobulin enhancer binding protein/ec [Endogenous Compound], interleukin 1/ec [Endogenous Compound], interleukin 10/ec [Endogenous Compound], interleukin 1beta/ec [Endogenous Compound], leucine zipper protein/ec [Endogenous Compound], mitogen activated protein kinase/ec [Endogenous Compound], phosphatidylinositol 3 kinase/ec [Endogenous Compound], protein SH3/ec [Endogenous Compound], STAT3 protein/ec [Endogenous Compound], transcription factor AP 1/ec [Endogenous Compound], transcription factor FOXP3/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], unclassified drug, glucocorticoid induced leucine zipper/ec [Endogenous Compound], genetic polymorphism, antiinflammatory activity, apoptosis, B lymphocyte activation, B lymphocyte differentiation, cardiovascular disease, cell differentiation, chromatin structure, diabetes mellitus, disease activity, disease control, DNA binding, down regulation, gene control, gene expression, genetic transcription, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35608Test
Frontiers in Immunology
LibKey Link

مصطلحات الفهرس: multicenter study, overall survival, phase 2 clinical trial, progression free survival, quality of life, randomized controlled trial, rectum, sigmoid, skin disease/si [Side Effect], transverse colon, article, treatment duration, unspecified side effect/si [Side Effect], B Raf kinase/ec [Endogenous Compound], adult, metastatic colorectal cancer/dt [Drug Therapy], monotherapy, disease exacerbation, drug efficacy, drug safety, drug tolerability, female, human, loading drug dose, male, metastatic colorectal cancer/dm [Disease Management], molecularly targeted therapy, aged, cetuximab/ae [Adverse Drug Reaction], cetuximab/cb [Drug Combination], cetuximab/cm [Drug Comparison], cetuximab/dt [Drug Therapy], cetuximab/to [Drug Toxicity], cetuximab/iv [Intravenous Drug Administration], epidermal growth factor receptor/ec [Endogenous Compound], irinotecan/ae [Adverse Drug Reaction], irinotecan/cb [Drug Combination], irinotecan/cm [Drug Comparison], irinotecan/dt [Drug Therapy], K ras protein/ec [Endogenous Compound], phosphatidylinositol 3 kinase/ec [Endogenous Compound], Ras protein/ec [Endogenous Compound], unclassified drug, n ras protein/ec [Endogenous Compound], cancer combination chemotherapy, cancer resistance, clinical article, controlled study, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37234Test
Clinical Colorectal Cancer
Click here for full text options
LibKey Link

مصطلحات الفهرس: kinetics, lymphocyte, nonhuman, PIR-International Protein Sequence Database, protein phosphorylation, review, RNA splicing, sensitivity analysis, sequence homology, signal transduction, systemic lupus erythematosus, T lymphocyte, ubiquitination, B lymphocyte receptor/ec [Endogenous Compound], BCR ABL protein/ec [Endogenous Compound], Bruton tyrosine kinase/ec [Endogenous Compound], carcinoembryonic antigen related cell adhesion molecule 1/ec [Endogenous Compound], CD19 antigen/ec [Endogenous Compound], cyclin D/ec [Endogenous Compound], Fc receptor IIb/ec [Endogenous Compound], glycogen synthase kinase 3beta/ec [Endogenous Compound], growth factor receptor bound protein 2/ec [Endogenous Compound], immunoglobulin A/ec [Endogenous Compound], immunoglobulin M/ec [Endogenous Compound], interferon regulatory factor 5/ec [Endogenous Compound], interleukin 12/ec [Endogenous Compound], interleukin 6/ec [Endogenous Compound], mitogen activated protein kinase 1/ec [Endogenous Compound], mitogen activated protein kinase 3/ec [Endogenous Compound], Myc protein/ec [Endogenous Compound], myeloid differentiation factor 88/ec [Endogenous Compound], non receptor protein tyrosine phosphatase 2/ec [Endogenous Compound], phosphatidylinositol 3 kinase/ec [Endogenous Compound], phosphatidylinositol kinase/ec [Endogenous Compound], phosphoinositide dependent protein kinase 1/ec [Endogenous Compound], protein kinase C/ec [Endogenous Compound], protein kinase Lyn/ec [Endogenous Compound], protein p85/ec [Endogenous Compound], protein SH2/ec [Endogenous Compound], protein tyrosine phosphatase 1B/ec [Endogenous Compound], synaptotagmin I/ec [Endogenous Compound], toll like receptor 1/ec [Endogenous Compound], unindexed drug, lupus vulgaris, adaptive immunity, Akt signaling, antibody production, autoimmune disease, autoimmunity, B lymphocyte, cell hyperplasia, downstream processing, genetic susceptibility, genome-wide association study, genotype phenotype correlation, human, hydrolysis, immune dysregulation, immunity, inflammation, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37633Test
Frontiers in Immunology
Click here for full text options
LibKey Link